从错误中学习：EGFR 突变的肾尿路上皮癌对吉非替尼的反应
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
作者信息
Fiorentino Michelangelo, Giunchi Francesca, Altimari Annalisa, Di Tullio Piergiorgio, Gruppioni Elisa, Martorana Giuseppe, Pinto Carmine
机构信息
Pathology Service, Addarii Institute of Oncology, Bologna, Italy.
出版信息
Oncologist. 2014 Apr;19(4):430. doi: 10.1634/theoncologist.2013-0346. Epub 2014 Mar 20.
Abstract
This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.
摘要
这封信描述了首例肾盂尿路上皮癌伴有罕见表皮生长因子受体（EGFR）双突变的病例对抗EGFR抑制剂吉非替尼产生临床反应的情况。应始终通过广谱突变分析来探索新的突变和意外的临床反应。
相似文献
1
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.从错误中学习：EGFR 突变的肾尿路上皮癌对吉非替尼的反应
Oncologist. 2014 Apr;19(4):430. doi: 10.1634/theoncologist.2013-0346. Epub 2014 Mar 20.
2
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
3
[Gefitinib-induced perforating dermatosis].[吉非替尼诱发的穿通性皮肤病]
Actas Dermosifiliogr. 2006 Apr;97(3):208-11. doi: 10.1016/s0001-7310(06)73383-x.
4
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.吉非替尼治疗的初治非小细胞肺癌患者肿瘤及血清中的表皮生长因子受体（EGFR）突变
J Thorac Oncol. 2006 Mar;1(3):260-7. doi: 10.1016/s1556-0864(15)31577-x.
5
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.吉非替尼用于治疗一名伴有表皮生长因子受体（EGFR）突变的肺鳞状细胞癌、体能状态较差的患者。
Intern Med. 2012;51(6):659-61. doi: 10.2169/internalmedicine.51.6386. Epub 2012 Mar 15.
6
7
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).亚洲临床精选晚期非小细胞肺癌患者中吉非替尼对比卡铂/紫杉醇一线治疗的 III 期、随机、开放标签、前瞻性研究的生物标志物分析和最终总生存结果（IPASS）。
J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.
8
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
9
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.物理尺寸对携带 EGFR 突变的非小细胞肺癌患者吉非替尼疗效的影响。
Lung Cancer. 2013 Sep;81(3):435-439. doi: 10.1016/j.lungcan.2013.05.021. Epub 2013 Jul 1.
10
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.化疗与吉非替尼在诱导血液系统肿瘤发生中的潜在相互作用。
Leukemia. 2007 Dec;21(12):2546-7. doi: 10.1038/sj.leu.2404851. Epub 2007 Jul 26.
引用本文的文献
1
Novel molecular targets for urothelial carcinoma.尿路上皮癌的新型分子靶点。
Expert Opin Ther Targets. 2015 Apr;19(4):515-25. doi: 10.1517/14728222.2014.987662. Epub 2015 Jan 30.
本文引用的文献
1
High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.高表皮生长因子受体免疫组织化学表达在膀胱尿路上皮癌中与外显子 19 和 21 中的 EGFR 突变无关：一项使用福尔马林固定、石蜡包埋存档组织的研究。
Hum Pathol. 2012 Oct;43(10):1590-5. doi: 10.1016/j.humpath.2011.11.016. Epub 2012 Mar 9.
2
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.非小细胞肺癌的表皮生长因子受体（EGFR）基因异质性导致对吉非替尼产生获得性耐药。
Int J Cancer. 2008 Dec 1;123(11):2480-6. doi: 10.1002/ijc.23868.
3
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.激酶结构域内的突变和表皮生长因子受体的截短在膀胱癌中是罕见事件：对治疗的启示。
Clin Cancer Res. 2006 Aug 1;12(15):4671-7. doi: 10.1158/1078-0432.CCR-06-0407.
Zotero 插件